Combining AURKA inhibition with immunotherapies such as checkpoint blockade or novel immune cell-based treatments may offer improved therapeutic outcomes by simultaneously disrupting the immunosuppressive tumor microenvironment. The gene discussed is AURKA; the disease is neoplasm.